News

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.

Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.

NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.

The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

Regulatory acceptance opens the door, but it neither guarantees approval nor repairs Novo's late start.

The FDA approved Eli Lilly's diabetes drug Mounjaro to cut down the risk of heart attack or stroke in high-risk adults with Type 2 diabetes.

A new FDA approval extends Lilly's blockbuster into cardiovascular risk reduction

Central banks across Asia and Europe are moving toward tighter policy as inflation stays on the radar, yet cash in the bank still offers limited income. That gap creates a clear opening for investors who want income that can keep working even as rates shift. This article looks at three stocks from the Dividend Powerhouses screener that currently offer 5%+ yields with covered, growing, and stable payouts. The three dividend stocks covered below are just a small sample of this income theme, and...

Novo Nordisk stock has given investors a difficult few years, with the share price down about 47.0% over the past three years, yet the broader valuation checks currently lean cheap rather than expensive. That contrast is drawing attention to whether the recent weakness has already reset expectations enough for long term holders. The roughly 47.0% share price decline over three years suggests sentiment has cooled sharply compared with earlier enthusiasm. The ongoing focus on GLP-1 obesity...

Regulatory acceptance expands Novo's addressable market, but Lilly filed first and may launch its competing pill sooner.

Deutsche Bank’s downgrade of Novo Nordisk (NVO) to Sell, following mixed second quarter results and obesity drug setbacks, has sharpened investor focus on the stock’s recent performance and current valuation. At a share price of US$47.19, Novo Nordisk has seen short term pressure build, with the share price return down 3.0% over the last day and about 5.0% over the past month. The year to date share price return is down 9.9% and the 1 year total shareholder return is down 13.5%, indicating...

China's drug regulator accepted Novo Nordisk's application for an oral version of Wegovy as the Danish company competes with Eli Lilly in the market

Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker’s ability to return to growth and navigate an impending patent cliff.

European equities traded in the US as American depositary receipts were trending lower late Thursday

The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.

Investing.com -- Deutsche Bank downgraded Novo Nordisk (NYSE:NVO) (CSE:NOVOb) to Sell from Hold and cut its price target by 9% to 265 Danish crowns from 290 crowns, flagging persisting concerns over the company’s growth trajectory. The stock fell more than 3% in Copenhagen trading Thursday.

Novo Nordisk (NYSE:NVO) has received a downgrade from Deutsche Bank, with analysts lowering their target price as midterm growth concerns and pipeline issues mount. The shares dropped 2.52% to DKK 297.25 as the broker adjusted its rating to 'sell', moving down from a previous 'hold' view...

Find insight on Novo Nordisk, Innovent Biologics, Ramsay Health Care and more in the latest Market Talks covering Health Care.

New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.

Deutsche Bank said Ziltivekimab is ‘now effectively out of the picture’ after the cardiovascular disease therapy failed a late-stage trial.

Novo Nordisk (NVO) said Thursday that China's National Medical Products Administration has accepted

European equities traded in the US as American depositary receipts were tracking lower late Wednesda

Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.

Aug 26 (Reuters) - Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

By Tharuniyaa Lakshmi and Utkarsh Hathi Aug 25 (Reuters) - European shares rose on Tuesday as investors took comfort from a softer-than-feared U.S. sanctions package on Iran and falling oil prices,

Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.

Eli Lilly and Novo Nordisk both dominated GLP-1 headlines in Q2 2026, but one company raised guidance while the other announced layoffs, pipeline writedowns, and a dramatic price cut. The split screen tells a story that goes beyond which drug sells more.